Loading...
XSHE
300009
Market cap2.28bUSD
Dec 05, Last price  
9.74CNY
1D
0.93%
1Q
-12.57%
Jan 2017
29.71%
IPO
202.67%
Name

Anhui Anke Biotechnology Group Co Ltd

Chart & Performance

D1W1MN
XSHE:300009 chart
P/E
23.04
P/S
6.42
EPS
0.42
Div Yield, %
2.59%
Shrs. gr., 5y
0.54%
Rev. gr., 5y
8.17%
Revenues
2.54b
-11.51%
127,769,584125,874,083156,490,022190,643,971227,930,127267,916,554337,940,099430,346,122542,405,933635,755,075849,216,4341,096,268,3151,461,550,2031,712,529,6691,701,417,2162,168,765,2052,331,062,7272,865,752,0592,536,042,781
Net income
707m
-16.56%
15,727,07822,713,57234,552,89444,570,47151,983,69163,322,66073,945,18289,870,067109,851,477136,254,700197,302,805277,742,623263,171,602124,465,864358,955,394206,629,495703,260,285847,229,426706,948,363
CFO
685m
-30.42%
29,662,11435,098,07926,043,95438,674,86547,427,2117,180,61153,800,82553,213,032108,684,214118,734,165258,005,072280,625,013287,490,590295,627,531464,796,376592,171,625698,977,608985,011,682685,371,947
Dividend
May 27, 20240.25 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Anhui Anke Biotechnology (Group) Co., Ltd. develops, produces, and markets pharmaceutical products in China and internationally. The company offers recombinant human growth hormone for injection under the Ansomone name; and recombinant human interferon alpha 2b lyophilized powder, liquid, and prefilled syringe for injection, as well as recombinant human interferon alpha 2b cream, eye drop, and suppository under the Anterferon name. It also provides anti-sperm antibody, semen leukocyte peroxidase staining, one-time semen processing, sperm hypo-osmotic staining, sperm life detection, sperm staining detection, sperm acrosin detection, sperm DNA fragmentation staining, and leptin and immunohistochemical diagnostic kits. In addition, the company offers adhesive plasters, oral solutions, topical preparations, and ointments; peptide APIs; beauty care and anti-aging products; and synthetic drugs in the form of oral powders, dripping pills, and tablets and capsules. Further, it provides autosomal, sex chromosome, autosomal and sex chromosome combination, and other kits, as well as paternity testing set packages; tumor biological immunotherapy products; and DNA testing professional services. The company was founded in 2000 and is based in Hefei, China.
IPO date
Oct 30, 2009
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT